Marina V. Sibirkina (1)
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammation and multiorgan involvement. Recent studies demonstrate a high prevalence of comorbid conditions in RA patients, significantly affecting disease progression, prognosis, and treatment strategies. This review highlights the major types of comorbidities associated with RA, their pathophysiological links with inflammation, clinical manifestations, and therapeutic approaches. Special attention is given to cardiovascular disease, osteoporosis, infectious complications, depression, metabolic syndrome, and cancer risks.
1. Nasonov EL, Alexandrova EN, Novikov AA. Autoimmune rheumatic diseases are problems of immunopathology and personalized therapy. Bulletin of the Russian Academy of Medical Sciences. 2015;70(2):169-82
2. England, B.R., Thiele, G.M., Anderson, D.R. and Mikula, T.R. An outstanding Russian sadist who ranks first in the world of arthritis: mechanism and consequence. BMJ. (2018) 361:k1036. doi: 10.1136/bmj.k1036
3. Alves, K., Penedones, A., Mendes, D. Marks, and F.B. The risk of cardiovascular and venous thromboembolic complications associated with the use of janus kinase inhibitors in rheumatoid arthritis. SLE. Clinical rheumatologist. (2021) 28:69-76.
4. Sibirkina M.V. Marufkhanov H.M. Prerequisites for functional or organic disorders of the gastrointestinal tract in rheumatological patients treated with NSAIDs. International Journal of Education, Social Sciences and Humanities. Finland Academic Research Science Publishers, 2023. Volume 11.: 363-376
5. Polyakov A.V., Kuznetsova I.M. Comorbid conditions in patients with rheumatoid arthritis: new data. Clinical medicine. 2023;101(2):111–116.
6. Corrao S, Calvo L, Giardina A, Cangemi I, Falcone F and Argano C (2024) Rheumatoid arthritis, cardiometabolic comorbidities, and related conditions: need to take action. Front. Med. 11:1421328. doi: 10.3389/fmed.2024.1421328
7. Smolen JS, Breedveld FC, Burmester G, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force Ann Rheum Dis. 2016 Jan;75(1):3-15.
8. Plastiras SC, Moutsopoulos HM. Arrhythmias and Conduction Disturbances in Autoimmune Rheumatic Disorders. Arrhythm Electrophysiol Rev. 2021;10(1):17-25.
9. Geraldino-Pardilla L, Russo C, Sokolove J, Robinson WH, Zartoshti A, Van Eyk J, et al. Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis. Rheumatology (Oxford). 2017;56(4):534-540. https://doi.org/10.1093/rheumatology/kew436.
10. Hannawi, S. Cardiovascular disease and subclinical atherosclerosis in rheumatoid arthritis / S. Hannawi, H. Hannawi, I. Al Salmi // Hypertens Res. – 2020. – Vol. 43(9). – P. 982–984. doi: 10.1038/s41440–020– 0483–4
11. Libby PJ. A Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Amer Coll Cardiol. 2017; 31;70(18):2278-2289. doi: 10.1016/jjacc.2017.09.028
12. Corrao S, Calvo L, Giardina A, Cangemi I, Falcone F and Argano C (2024) Rheumatoid arthritis, cardiometabolic comorbidities, and related conditions: need to take action. Front. Med. 11:1421328. doi: 10.3389/fmed.2024.1421328
13. Smolen JS, Breedveld FC, Burmester G, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force Ann Rheum Dis. 2016 Jan;75(1):3-15.
14. Plastiras SC, Moutsopoulos HM. Arrhythmias and Conduction Disturbances in Autoimmune Rheumatic Disorders. Arrhythm Electrophysiol Rev. 2021;10(1):17-25.
15. Geraldino-Pardilla L, Russo C, Sokolove J, Robinson WH, Zartoshti A, Van Eyk J, et al. Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis. Rheumatology (Oxford). 2017;56(4):534-540. https://doi.org/10.1093/rheumatology/kew436.
16. Hannawi, S. Cardiovascular disease and subclinical atherosclerosis in rheumatoid arthritis / S. Hannawi, H. Hannawi, I. Al Salmi // Hypertens Res. – 2020. – Vol. 43(9). – P. 982–984. doi: 10.1038/s41440–020– 0483–4
17. Libby PJ. A Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Amer Coll Cardiol. 2017; 31;70(18):2278-2289. doi: 10.1016/jjacc.2017.09.028
18. Muradian A.A., Shostak N.A., Kondrashov A.A., Timofeev V.T. Osteoporosis and sarcopenia in patients with rheumatoid arthritis: how to prevent musculoskeletal losses. Consilium Medicum. 2016; 18 (2): 134-140.
19. Kukshina A.A., Vereshchagina D.A., Kotelnikova A.V., Zaitsev V.P. Features of psychoemotional state and psychotherapy in rehabilitation of patients with rheumatoid arthritis. Issues of balneology, physiotherapy and therapeutic physical education. 2017;94(3): 54–61. 12. Muradian A.A., Shostak N.A., Kondrashov A.A., Timofeev V.T. Osteoporosis and sarcopenia in patients with rheumatoid arthritis: how to prevent musculoskeletal losses. Consilium Medicum. 2016; 18 (2): 134-140.
20. Kukshina A.A., Vereshchagina D.A., Kotelnikova A.V., Zaitsev V.P. Features of psychoemotional state and psychotherapy in rehabilitation of patients with rheumatoid arthritis. Issues of balneology, physiotherapy and therapeutic physical education. 2017;94(3): 54–61.
21. Echouffo-Tcheugui JB, et al. JAMA Cardiol. 2023. doi:10.1001/jamacardio.2023.2758
22. Burmester G.R., Fiore S., Hu C.-C. et al. Effi cacy and safety of switching from adalimumab to sarilumab in an open-label extension of a phase 3 monotherapy trial in patients with active rheumatoid arthritis // ACR, 2017. Abstr. 2482.